Actos Sales Grow On Avandia’s Woes, Takeda Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. sales of the diabetes therapy pioglitazone were up 19.2 percent year over year, Takeda reports.
You may also be interested in...
Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.